Bayer Secures FDA Approval for Hemophilia A Treatment, Jivi

Hemophilia A patients have another treatment option. This morning the U.S. Food and Drug Administration (FDA) gave the nod to Bayer AG’s new treatment, Jivi (BAY94-9027).